Qiu Xiusheng相关文献与解析，生知库 | 链接生命科学的每一步

TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma

TFCP2L1通过调节肝细胞癌中的NANOG/STAT3通路来驱动干细胞特性并增强其对索拉非尼治疗的耐药性

Qiu, Dongbo; Wang, Tiantian; Xiong, Yi; Li, Kun; Qiu, Xiusheng; Feng, Yuan; Lian, Qinghai; Qin, Yunfei; Liu, Kunpeng; Zhang, Qi; Jia, Changchang

肿瘤

Hepatocyte nuclear factor 1A suppresses innate immune response by inducing degradation of TBK1 to inhibit steatohepatitis.

肝细胞核因子 1A 通过诱导 TBK1 降解来抑制先天免疫反应，从而抑制脂肪性肝炎

期刊:Genes and Diseases

影响因子:9.4

doi:10.1016/j.gendis.2022.05.029

He Jinyong, Du Cong, Peng Xuyun, Hong Weilong, Qiu Dongbo, Qiu Xiusheng, Zhang Xingding, Qin Yunfei, Zhang Qi

细胞生物学

发表日期：2023

文献求助收藏

Key genes associated with non-alcoholic fatty liver disease and hepatocellular carcinoma with metabolic risk factors

与非酒精性脂肪肝和肝细胞癌相关的关键基因及其代谢风险因素

期刊:Frontiers in Genetics

影响因子:2.8

doi:10.3389/fgene.2023.1066410

Yang, Fan; Ni, Beibei; Lian, Qinghai; Qiu, Xiusheng; He, Yizhan; Zhang, Qi; Zou, Xiaoguang; He, Fangping; Chen, Wenjie

PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.

PROZ 与索拉非尼敏感性相关，可能成为增强肝细胞癌联合免疫疗法疗效的潜在靶点

期刊:Genes

影响因子:2.8

doi:10.3390/genes13091535

Chen Yinkui, Qiu Xiusheng, Wu Donghao, Lu Xu, Li Guanghui, Tang Yongsheng, Jia Changchang, Xiong Zhiyong, Wang Tiantian

细胞生物学

发表日期：2022

文献求助收藏

MUTYH is a potential prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma

MUTYH是一种潜在的预后生物标志物，与肝细胞癌中的免疫浸润相关。

期刊:Liver Research

影响因子:2.1

doi:10.1016/j.livres.2022.12.002

Yang, Fan; Lian, Qinghai; Ni, Beibei; Qiu, Xiusheng; He, Yizhan; Zou, Xiaoguang; He, Fangping; Chen, Wenjie

SNRK modulates mTOR-autophagy pathway for liver lipid homeostasis in MAFLD.

SNRK 调节 mTOR-自噬通路，从而维持 MAFLD 中的肝脏脂质稳态

TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma

TFCP2L1通过调节肝细胞癌中的NANOG/STAT3通路来驱动干细胞特性并增强其对索拉非尼治疗的耐药性

Hepatocyte nuclear factor 1A suppresses innate immune response by inducing degradation of TBK1 to inhibit steatohepatitis.

肝细胞核因子 1A 通过诱导 TBK1 降解来抑制先天免疫反应，从而抑制脂肪性肝炎

Key genes associated with non-alcoholic fatty liver disease and hepatocellular carcinoma with metabolic risk factors

与非酒精性脂肪肝和肝细胞癌相关的关键基因及其代谢风险因素

PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.

PROZ 与索拉非尼敏感性相关，可能成为增强肝细胞癌联合免疫疗法疗效的潜在靶点

MUTYH is a potential prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma

MUTYH是一种潜在的预后生物标志物，与肝细胞癌中的免疫浸润相关。